Highlights:

• 100 million+ ECGs are performed annually in the USA.
• AIML's proprietary "Long ECG Neural Net" reduces labeling of long ECGs from several days to under 5 minutes.
• Provides unsurpassed accuracy, depth and insight into the cardiac data.

VICTORIA, BC / ACCESSWIRE / May 6, 2024 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is proud to introduce its proprietary Long ECG Neural Net (L-ECG NN). The L-ECG NN provides cardiologists, researchers, pharmaceuticals and others, with a fast, accurate and comprehensive tool for the in-depth analysis and feature extraction of ECGs.

The Need for Improved Utilization of ECG Data

• "The ECG is the most commonly performed cardiovascular diagnostic procedure, with >100 million ECGs obtained annually in the United States."¹ (AHA Journals)
• Typical 24/48 hour-long ECGs, that are used in clinical trial, drug discovery, and specialist cases, take many days of effort for in-depth labeling, when relying on conventional, semi-automatic methods.
• "Even for an experienced cardiologist, accurately interpreting the ECG for a patient with concurrent arrhythmias is challenging" ... "there is an urgent unmet need for an automated or assisted multilabel ECG diagnostic framework, supported by artificial intelligence technology."² (The Lancet)

The L-ECG NN Feature Set Advantage

AIML's Long ECG Neural Net displays many advantages over conventional methods of analyzing ECG data:

• Accurate: The L-ECG NN was trained and tested on human ECG data, providing accurate labeling with minimal (2ms) error.
• In-depth: Our proprietary AI analysis algorithm enables in-depth analysis and feature extraction of ECGs, allowing clinicians and researchers to quickly identify specific changes to the heartbeats of a long recording.
• Versatile: Our advanced AI analysis algorithm provides deep analysis of ECGs from multiple sources (e.g., holters, sleep studies, clinical drug trials).
• Comprehensive: While rudimentary traditional methods of ECG analysis only spot the R-peak, we label every waveform and its duration, providing comprehensive cardiac data insights.
• Fast: We are able to label all ECG features within minutes for ECGs of any size, rather than in days, as is the present case.
• Future potential: The L-ECG NN has the potential of using the features extracted to detect and predict cardiovascular diseases, and discovering new digital biomarkers for cardiac and chronic patients.

Product Configurations

The L-ECG NN is available for hardware integration (use in 1- Lead ECG wearable monitors, 1 or 3-lead Holter monitors, and more), or for use online.

• Available as a REST API, allowing developers to integrate L-ECG NN into third-party applications.
• A web application for easy use, without technical knowledge.

Our Targeted Market Segments/Users

While the potential user base for our technology is both broad and deep, we have identified several potential market segments that represent our "path of least resistance" to market penetration. Some of these include:

• Pharmaceuticals & Clinical Drug Trials
• Device/ECG hardware companies (e.g. Holter monitors or patches)
• Researchers
• Cardiology specialists

Future Development Plans

AIML has several plans for the expansion of both the potential use and the users of the L-ECG NN technology going forward. Some of these include:

• Regulatory approval: FDA submission for approval as a medical device.
• Online access: An incorporated User Interface (UI) for users to directly interact with the NN Store. Users will be able to directly upload their ECG data and have a full display of resulting graphs and labels to analyze and download.
• Diagnosis: Training of the L-ECG NN to analyze ECGs for heart abnormalities to accelerate and automate diagnoses
• Prediction: Accelerate and, eventually, automate the analysis of existing ECG databases to enable early detection and prediction of cardiovascular diseases (CVDs).

About AI/ML Innovations Inc.

AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

On behalf of the Board of Directors
Tim Daniels, Executive Chairman

For more information about AI/ML Innovations:
For detailed information please see AI/ML's website or the Company's filed documents at
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For AI/ML Innovations Investors

Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives, and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at .